SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-21-004075
Filing Date
2021-11-10
Accepted
2021-11-10 16:07:02
Documents
13
Period of Report
2021-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alna-20211110.htm   iXBRL 8-K 52247
2 EX-99.1 alna-ex99_1.htm EX-99.1 104128
  Complete submission text file 0000950170-21-004075.txt   290963

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT alna-20211110.xsd EX-101.SCH 2499
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT alna-20211110_pre.xml EX-101.PRE 10685
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT alna-20211110_lab.xml EX-101.LAB 14564
6 EXTRACTED XBRL INSTANCE DOCUMENT alna-20211110_htm.xml XML 5124
Mailing Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462
Business Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462 617-467-4577
Allena Pharmaceuticals, Inc. (Filer) CIK: 0001624658 (see all company filings)

IRS No.: 452729920 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38268 | Film No.: 211396562
SIC: 2836 Biological Products, (No Diagnostic Substances)